Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AcuTect Phase IV Study Will Examine Utility Of Negative Thrombosis Scans

This article was originally published in The Gray Sheet

Executive Summary

The clinical utility of a negative test result in the imaging of venous thrombosis will be examined in a post-approval study of Diatide's AcuTect. The apcitide technetium Tc 99m kit was approved by FDA Sept. 14.

You may also be interested in...

Schering Entering Radiopharmaceuticals Market Via $128 Mil. Diatide Deal

Schering AG is looking to accelerate its expansion into the worldwide radiopharmaceuticals market through the acquisition of Diatide. The $128 mil. cash deal was announced Sept. 20.

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts